Prenatal Testing Methods
Log in to starLast updated Nov 9, 2026
Prenatal genetic testing is either screening, which estimates a probability, or diagnostic, which gives a definitive answer from fetal or placental cells. That distinction is the center of prenatal counseling and informed consent. This page is the map: it covers serum screening and when each test is available, and it links out for the detail on cfDNA screening, CVS and amniocentesis, and the ultrasound findings that prompt testing.
Screening Tests (Non-Invasive)
-
cfDNA screening (NIPS): cell-free DNA in maternal blood, mostly placental, available from 10 weeks' gestation. Highest detection for trisomy 21, but it is a screening test: a positive result is confirmed by CVS or amniocentesis. Fetal fraction, positive predictive value, expanded panels, and test failures are on the cfDNA screening page.
-
Maternal serum screening:
- First trimester combined screening (11–13+6 weeks): Nuchal translucency (NT) measurement by ultrasound + serum PAPP-A + free beta-hCG. Detection rate ~82–87% for trisomy 21.
- Quad screen (15–22 weeks): AFP, hCG, unconjugated estriol, inhibin A. Detection rate ~81% for trisomy 21. Also screens for trisomy 18 and open neural tube defects (elevated AFP).
- Sequential/integrated screening: Combines first and second trimester results for improved detection rates (~90–95%).
- Key analyte patterns for trisomy 21: Low AFP, high hCG, low uE3, high inhibin A.
-
Ultrasound markers:
- First trimester: increased nuchal translucency, absent nasal bone, tricuspid regurgitation, reversed ductus venosus flow
- Second trimester: echogenic bowel, short femur/humerus, echogenic intracardiac focus, pyelectasis, ventriculomegaly (soft markers)
- Structural anomalies (cardiac defects, omphalocele, duodenal atresia), growth restriction, hydrops, and abnormal fluid may prompt diagnostic testing
Diagnostic Tests (Invasive)
- Chorionic villus sampling (CVS) at 10–13 weeks samples placenta, so results come earlier, with confined placental mosaicism as the main caveat.
- Amniocentesis at 15–18 weeks or later samples fetal cells in amniotic fluid.
Procedure, loss risk, the tests each sample supports, and the CVS and amniocentesis comparison are on the invasive prenatal testing page.
When Each Test Is Available
| Test | Gestational age |
|---|---|
| cfDNA screening | 10 weeks onward |
| CVS | 10–13 weeks |
| First trimester combined screening | 11–13+6 weeks |
| Amniocentesis | 15–18 weeks, can be done later |
| Quad screen | 15–22 weeks |
- Informed consent is paramount: Genetic counselors must ensure patients understand the difference between screening and diagnostic testing, the limitations of each, and the implications of results before testing.
- Cascade decision-making: A positive screening result (cfDNA, serum screen, or ultrasound finding) often leads to offering diagnostic testing. A negative screening result reduces but does not eliminate risk.
- PPV depends on prevalence: A positive cfDNA result for trisomy 21 in a 38-year-old has a much higher PPV than the same result in a 25-year-old, because the baseline prevalence of trisomy 21 increases with maternal age.
- Patient autonomy: Prenatal testing is always optional. Results may be used for pregnancy management, preparation, or termination. The decision belongs to the patient.
- Screening is not diagnosis: cfDNA and serum screening cannot replace diagnostic testing.
- CVS cannot test for neural tube defects: Amniotic fluid AFP is needed; CVS does not provide access to amniotic fluid.
- Neither CVS nor amniocentesis detects all conditions: These procedures provide material for cytogenetic and molecular testing, but the specific tests ordered determine what is detected.
- Maternal cell contamination: Possible in both CVS and amniocentesis samples; can lead to erroneous results, particularly in molecular testing. Laboratories perform maternal cell contamination studies to mitigate this.
"CVS is Chorionic, early, and Cannot test NTDs": CVS samples placenta, is done at 10–13 weeks, and cannot test for neural tube defects.
"NIPT is Not a dIagnostic Prenatal Test": the acronym itself is a reminder. Always confirm positive NIPT results with amniocentesis or CVS.
"Hi is high in Down": on the quad screen, HCG and Inhibin A are high in trisomy 21; everything else (AFP, uE3) is down. So in Down syndrome: hCG ↑, inhibin A ↑, AFP ↓, uE3 ↓.
"E'dward = Everything downward": in trisomy 18 (Edwards), all four quad-screen analytes are decreased: AFP ↓, hCG ↓, uE3 ↓, inhibin A ↓ (or normal).
"Patau = Perfect, except PAPP-A Plummets": trisomy 13 looks roughly unremarkable on serum screening except that first-trimester PAPP-A is markedly low. Detection relies more on NT and confirmatory diagnostic testing than analyte pattern.